- Home
- LUCY vs PPBT Comparison
LUCY vs PPBT Comparison
Compare LUCY & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LUCY | PPBT |
|---|---|---|
| Founded | 2017 | 2010 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Ophthalmic Goods | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.7M | 6.5M |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | LUCY | PPBT |
|---|---|---|
| Price | $1.35 | $0.70 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 251.5K | ★ 735.2K |
| Earning Date | 11-13-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,392,547.00 | N/A |
| Revenue This Year | $80.76 | N/A |
| Revenue Next Year | $210.34 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 53.22 | N/A |
| 52 Week Low | $1.29 | $0.53 |
| 52 Week High | $7.08 | $5.20 |
Technical Indicators
Market Signals| Indicator | LUCY | PPBT |
|---|---|---|
| Relative Strength Index (RSI) | 40.79 | 41.65 |
| Support Level | $1.36 | $0.69 |
| Resistance Level | $1.43 | $0.87 |
| Average True Range (ATR) | 0.10 | 0.05 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 8.57 | 17.03 |
Price Performance
Historical ComparisonAbout LUCY Innovative Eyewear Inc.
Innovative Eyewear Inc is engaged in developing and selling eyeglasses and sunglasses, which are designed to allow customers to remain connected to their digital lives, while also offering prescription eyewear and sun protection. Its products include Lucyd Lyte, Nautica, Eddie Bauer, Lucyd Armor line, and Reebok.
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.